While clinical data is limited, peptide therapy may have a place in hormone regulation
The closest human evidence in its drug class is Athira Pharma's fosgonimeton (ATH-1017), a structurally distinct molecule in the same HGF/c-Met program whose Phase 2/3 LIFT-AD Alzheimer's trial failed its primary endpoint in September 2024 (GST 0.08, P=.70)
What makes it a better choice: Comprehensive coverage for foundational daily nutrient support Women-focused formulation instead of a generic multivitamin approach Twice-daily dosing , which can support better absorption and gentler tolerance for some women Bioavailable nutrients , which matter when digestion and intake are already compromised Support for energy, metabolism, hair, skin, immune health, and overall resilience For women on GLP-1, that combination matters
This coordinated response was fully reversed upon refeeding, demonstrating a rapid and reversible form of metabolic adaptation (Supplementary Fig